3/23
07:30 am
xlo
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Low
Report
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
3/17
05:14 pm
xlo
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
Low
Report
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
3/17
04:45 pm
xlo
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
Low
Report
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
3/12
08:30 am
xlo
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
Medium
Report
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
3/2
08:01 am
xlo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/2
08:00 am
xlo
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Medium
Report
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
3/2
07:30 am
xlo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/12
02:35 am
xlo
Xilio Therapeutics prices $40M stock offering [Seeking Alpha]
Medium
Report
Xilio Therapeutics prices $40M stock offering [Seeking Alpha]
2/11
09:34 pm
xlo
Xilio Therapeutics Announces Pricing of Underwritten Offering
Medium
Report
Xilio Therapeutics Announces Pricing of Underwritten Offering
1/8
08:30 am
xlo
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
Low
Report
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
12/30
04:16 pm
xlo
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Xilio Therapeutics (NASDAQ:XLO) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.